ABT vs EBS
Abbott Laboratories (ABT) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. EBS currently screens at market cap $416.4M.
Not investment advice. Open the ABT and EBS stock pages for the full models.
Not investment advice.